Sun Nuclear Acquires Oncospace, AI-Focused Radiation Oncology Software Provider

This strategic move underscores the Sun Nuclear commitment to leverage cutting-edge technology to improve treatment outcomes on behalf of their customers.

Sun Nuclear, a Mirion Medical company, today announced the acquisition of Oncospace, a company providing cloud-based, AI-powered solutions for the radiation oncology community.

This strategic move underscores the Sun Nuclear commitment to leverage cutting-edge technology to improve treatment outcomes on behalf of our customers.

Oncospace’s AI and machine-learning technologies are designed to develop data-driven, physician-centric solutions that optimize patient outcomes. Since its inception in 2018, Oncospace has launched two main offerings:

  • Gateway: A Treatment Planning Conversion solution for Philips Pinnacle users, which converts patient archives to modern treatment planning solutions, such as Raysearch Raystation and Varian Medical Systems® Eclipse. While originally developed for prostate treatments, this solution has since expanded to head and neck radiotherapy, with future offerings planned.
  • A Predictive Plan Quality and Feasibility solution, which leverages the AI approach of machine learning to analyze thousands of clinical treatment plans and derive achievable, best-practice dosimetry goals for plan optimization and evaluation.

“We are excited to welcome Oncospace into the Sun Nuclear family,” said Luis Rivera, Sun Nuclear president and Mirion Medical executive vice president. “By incorporating the Oncospace solutions dependent on AI and machine-learning capabilities, Sun Nuclear is affirming our commitment to drive innovation in radiation therapy. We look forward to the positive impact this will have on our software roadmap.”

By informing actions through harnessing vital information, the Oncospace offerings address the demands of radiation oncology professionals while improving the precision and efficiency of radiation therapy planning, thus enhancing the overall quality of care and outcomes. This acquisition aligns with the Sun Nuclear focus of enhancing the quality and accessibility of radiation therapy, ensuring that patients receive the best possible treatment.

Oncospace software will be featured in Sun Nuclear’s booth at ESTRO 2025, May 2-6, in Vienna, Austria. ESTRO is the annual congress for the European Society for Radiotherapy and Oncology and includes Europe’s largest industry exhibition in radiation oncology.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

April 30, 2025

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

April 24, 2025

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.